obesity drug news today glp-1 september 29 2025 There's lots going on this month at FDA in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Warning Letters New Daily GLP-1 Weight Loss

J Clin Endocrinol Metab (2020) 105(3):80320

Medicine Today

Semaglutide, liraglutide, and dulaglutide have all demonstrated modest systolic blood pressure reductions in clinical studies

Patient and public involvement This study investigated a well defined research question on a potential adverse event of GLP1 receptor agonists that is broadly recognised for its potential impact on patients, and that has been raised as a drug safety concern by drug regulatory agencies

GLP-1 Pipeline Update: November 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid

Another common effect is reduced cravings, especially for highly processed, high-calorie foods